Peter L Stern

Summary

Affiliation: University of Manchester
Country: UK

Publications

  1. doi request reprint Therapy of human papillomavirus-related disease
    Peter L Stern
    Paterson Institute for Cancer Research, University of Manchester, Manchester M20 4BX, UK
    Vaccine 30:F71-82. 2012
  2. ncbi request reprint Recent developments in human papillomavirus vaccines
    Peter L Stern
    Cancer Research UK Immunology Group, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester, M20 4BX, UK
    Expert Opin Investig Drugs 13:959-71. 2004
  3. ncbi request reprint Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination
    Peter L Stern
    CR UK Immunology Group, Department of Immunology, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester M20 4BX, UK
    J Clin Virol 32:S72-81. 2005
  4. ncbi request reprint Combination of vaccination and chimeric receptor expressing T cells provides improved active therapy of tumors
    Hui Rong Jiang
    Cancer Research U K Immunology Group, Paterson Institute for Cancer Research, University of Manchester and Christie Hospital National Health Service Trust, Manchester M20 4BX, UK
    J Immunol 177:4288-98. 2006
  5. ncbi request reprint Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination
    Lucy J C Smyth
    Cancer Research UK Immunology Group, Paterson Institute for Cancer Research, Christie Hospital, Manchester, United Kingdom
    Clin Cancer Res 10:2954-61. 2004
  6. ncbi request reprint Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins
    Emma J Davidson
    Immunology Group, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester, United Kingdom
    Cancer Res 63:6032-41. 2003
  7. doi request reprint An MVA-based vaccine targeting the oncofetal antigen 5T4 in patients undergoing surgical resection of colorectal cancer liver metastases
    Eyad Elkord
    CRUK Immunology, Medical Oncology Groups, Paterson Institute for Cancer Research, University of Manchester, Christie Hospital NHS Trust, Manchester, UK
    J Immunother 31:820-9. 2008
  8. ncbi request reprint Use of adenoviruses encoding CD40L or IL-2 against B cell lymphoma
    El Kahina Meziane
    CRUK Immunology Group, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester, United Kingdom
    Int J Cancer 111:910-20. 2004
  9. ncbi request reprint Adoptive transfer of T(reg) depleted autologous T cells in advanced renal cell carcinoma
    Fiona C Thistlethwaite
    Cancer Research UK Department of Medical Oncology, University of Manchester and Christie Hospital NHS Foundation Trust, Manchester, UK
    Cancer Immunol Immunother 57:623-34. 2008
  10. ncbi request reprint Immunotherapy for gastrointestinal cancer: current status and strategies for improving efficacy
    Eyad Elkord
    University of Manchester, Paterson Institute for Cancer Research, Department of Medical Oncology, Wilmslow Road, Manchester M20 4BX, UK
    Expert Opin Biol Ther 8:385-95. 2008

Collaborators

Detail Information

Publications48

  1. doi request reprint Therapy of human papillomavirus-related disease
    Peter L Stern
    Paterson Institute for Cancer Research, University of Manchester, Manchester M20 4BX, UK
    Vaccine 30:F71-82. 2012
    ..This article forms part of a special supplement entitled "Comprehensive Control of HPV Infections and Related Diseases" Vaccine Volume 30, Supplement 5, 2012...
  2. ncbi request reprint Recent developments in human papillomavirus vaccines
    Peter L Stern
    Cancer Research UK Immunology Group, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester, M20 4BX, UK
    Expert Opin Investig Drugs 13:959-71. 2004
    ..The possibility of combined prophylactic and therapeutic vaccines may offer the best chance for a significant reduction in the incidence of death from cervical cancer worldwide...
  3. ncbi request reprint Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination
    Peter L Stern
    CR UK Immunology Group, Department of Immunology, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester M20 4BX, UK
    J Clin Virol 32:S72-81. 2005
    ..It seems likely that combined prophylactic and therapeutic vaccine approaches could offer the best prospect for any significant reduction in death from cervical cancer worldwide...
  4. ncbi request reprint Combination of vaccination and chimeric receptor expressing T cells provides improved active therapy of tumors
    Hui Rong Jiang
    Cancer Research U K Immunology Group, Paterson Institute for Cancer Research, University of Manchester and Christie Hospital National Health Service Trust, Manchester M20 4BX, UK
    J Immunol 177:4288-98. 2006
    ..This synergistic effect was lost without delivery of the BMDC. Our findings suggest that combining engineered T cells with specific vaccination strategies can improve the active tumor therapy...
  5. ncbi request reprint Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination
    Lucy J C Smyth
    Cancer Research UK Immunology Group, Paterson Institute for Cancer Research, Christie Hospital, Manchester, United Kingdom
    Clin Cancer Res 10:2954-61. 2004
    ..The purpose is to study the immunogenicity of heterologous prime-boost human papillomavirus (HPV) oncogene vaccination in patients with anogenital intraepithelial neoplasia (AGIN)...
  6. ncbi request reprint Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins
    Emma J Davidson
    Immunology Group, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester, United Kingdom
    Cancer Res 63:6032-41. 2003
    ..Local immune infiltration may be a critical factor in potential responsiveness to vaccine therapy in HPV-associated neoplasia and should be carefully monitored in future placebo-controlled trials of immunotherapy for VIN...
  7. doi request reprint An MVA-based vaccine targeting the oncofetal antigen 5T4 in patients undergoing surgical resection of colorectal cancer liver metastases
    Eyad Elkord
    CRUK Immunology, Medical Oncology Groups, Paterson Institute for Cancer Research, University of Manchester, Christie Hospital NHS Trust, Manchester, UK
    J Immunother 31:820-9. 2008
    ..These observations warrant more studies to identify the precise underlying mechanisms...
  8. ncbi request reprint Use of adenoviruses encoding CD40L or IL-2 against B cell lymphoma
    El Kahina Meziane
    CRUK Immunology Group, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester, United Kingdom
    Int J Cancer 111:910-20. 2004
    ..0001). Our study strongly supports the use of Ad-CD40L and Ad-IL-2 combination therapy for the treatment of patients with B cell lymphoma...
  9. ncbi request reprint Adoptive transfer of T(reg) depleted autologous T cells in advanced renal cell carcinoma
    Fiona C Thistlethwaite
    Cancer Research UK Department of Medical Oncology, University of Manchester and Christie Hospital NHS Foundation Trust, Manchester, UK
    Cancer Immunol Immunother 57:623-34. 2008
    ..The aim of this study was to assess the feasibility and safety of adoptive transfer of CD25(+) depleted autologous T cells in patients with advanced renal cell carcinoma and to examine resulting changes in lymphocyte subsets...
  10. ncbi request reprint Immunotherapy for gastrointestinal cancer: current status and strategies for improving efficacy
    Eyad Elkord
    University of Manchester, Paterson Institute for Cancer Research, Department of Medical Oncology, Wilmslow Road, Manchester M20 4BX, UK
    Expert Opin Biol Ther 8:385-95. 2008
    ..Despite improvement in conventional strategies for treating gastrointestinal (GI) carcinoma, large numbers of patients still suffer from incurable or progressive disease...
  11. ncbi request reprint Vaccine and antibody-directed T cell tumour immunotherapy
    Said Dermime
    Immunology, Cancer Research UK Groups, Paterson Institute for Cancer Research and University of Manchester, Christie Hospital NHS Trust, Manchester M20 4BX, UK
    Biochim Biophys Acta 1704:11-35. 2004
    ....
  12. ncbi request reprint Cell surface 5T4 antigen is transiently upregulated during early human embryonic stem cell differentiation: effect of 5T4 phenotype on neural lineage formation
    Christopher M Ward
    Cancer Research UK Immunology Group, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK
    Exp Cell Res 312:1713-26. 2006
    ....
  13. ncbi request reprint Immunotherapy success in prophylaxis cannot predict therapy: prime-boost vaccination against the 5T4 oncofoetal antigen
    Sumia Ali
    CRUK Immunology Group, Paterson Institute of Cancer Research, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK
    Cancer Immunol Immunother 56:165-80. 2007
    ....
  14. doi request reprint Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4)
    Eyad Elkord
    CR UK Immunology Group, Paterson Institute for Cancer Research, University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, Manchester, M20 4BX, UK
    Cancer Immunol Immunother 58:1657-67. 2009
    ..More than half of the patients showed phenotypes consistent with relative immune suppression and/or escape highlighting the complexity of positive and negative factors challenging any simple correlation with clinical outcome...
  15. ncbi request reprint CD4+ T-cell recognition of human 5T4 oncofoetal antigen: implications for initial depletion of CD25+ T cells
    Eyad Elkord
    Department of Immunology, Paterson Institute for Cancer Research, University of Manchester, Wilmslow Road, Manchester M20 4BX, UK
    Cancer Immunol Immunother 57:833-47. 2008
    ..We have recently shown that CD8(+) T cells recognizing h5T4 can be generated in the absence of CD4(+) T cells from peripheral blood lymphocytes of human healthy individuals...
  16. doi request reprint Regulation of autologous immunity to the mouse 5T4 oncofoetal antigen: implications for immunotherapy
    Fernanda V Castro
    Immunology Group, Paterson Institute for Cancer Research, University of Manchester, Withington, UK
    Cancer Immunol Immunother 61:1005-18. 2012
    ..The efficacy of 5T4 and some other TAA vaccines may be limited by the combination of TAA-specific T regs, the deletion and/or alternative differentiation of CD4 T cells as well as the absence of distinct subsets of CD8 T cells...
  17. doi request reprint Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma
    Christy Ralph
    Department of Medical Oncology, School of Cancer, Enabling Sciences and Technology, University of Manchester, Manchester, United Kingdom
    Clin Cancer Res 16:1662-72. 2010
    ..Cytotoxic T lymphocyte antigen 4 (CTLA4), a key negative regulator of T-cell activation, is targeted by the antibody tremelimumab to release potentially useful antitumor activity...
  18. ncbi request reprint Adoptive transfer of anti-idiotypic T cells cure mice of disseminated B cell lymphoma
    Anne C Armstrong
    Cancer Research UK Department of Medical Oncology, Paterson Institute of Cancer Research, Christie Hospital NHS Trust, Manchester, UK
    J Immunother 27:227-31. 2004
    ..This line has been used to successfully treat mice with disseminated lymphoma supporting the clinical use of idiotype specific T cells...
  19. ncbi request reprint Human papillomavirus type 16 E2- and L1-specific serological and T-cell responses in women with vulval intraepithelial neoplasia
    Emma J Davidson
    Immunology Group, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK
    J Gen Virol 84:2089-97. 2003
    ..In spite of previous studies showing the immunogenicity of E2 in eliciting primary T-cell responses in vitro, there was a low prevalence of E2 responses in the VIN patients and controls (2/18 vs 0/17)...
  20. ncbi request reprint The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens
    Ryan D Guest
    Cancer Research UK, Department of Medical Oncology, University of Manchester and Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester M20 4BX, UK
    J Immunother 28:203-11. 2005
    ..These results show that a spacer is not necessary for optimal activity of CIRs but that the optimal design varies...
  21. doi request reprint CXCL12 receptor preference, signal transduction, biological response and the expression of 5T4 oncofoetal glycoprotein
    Owen J McGinn
    Immunology Group, Paterson Institute for Cancer Research, University of Manchester, Manchester M13 9PT, UK
    J Cell Sci 125:5467-78. 2012
    ....
  22. doi request reprint Clinical and immunologic results of a phase II trial of sequential imiquimod and photodynamic therapy for vulval intraepithelial neoplasia
    Ursula Winters
    School of Cancer and Imaging, University of Manchester, St Mary s Hospital, Immunology Group, Paterson Institute for Cancer Research, University of Manchester, Manchester, United Kingdom
    Clin Cancer Res 14:5292-9. 2008
    ..Indeed, there is evidence that immunosuppressed individuals have higher rates of VIN, suggesting immune control is relevant...
  23. ncbi request reprint CD8 T-cell recognition of human 5T4 oncofetal antigen
    Lucy J C Smyth
    Immunology Group, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester, United Kingdom
    Int J Cancer 119:1638-47. 2006
    ..In conclusion, there is a repertoire of CD8 T cell recognition of 5T4 in normal human donors and some candidate HLA-A*0201 epitopes have been identified...
  24. pmc CXCR4 mediated chemotaxis is regulated by 5T4 oncofetal glycoprotein in mouse embryonic cells
    Thomas D Southgate
    Immunology Group, Paterson Institute for Cancer Research, University of Manchester, Manchester, United Kingdom
    PLoS ONE 5:e9982. 2010
    ....
  25. ncbi request reprint Novel vectors for homologous recombination strategies in mouse embryonic stem cells: an ES cell line expressing EGFP under control of the 5T4 promoter
    Flor M Perez-Campo
    Stem Cell Biology Group, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Wilmslow Road, Manchester, UK
    Exp Cell Res 313:3604-15. 2007
    ..These vectors provide researchers with a rapid method of modifying specific ES cell genes to study cellular differentiation and embryonic development...
  26. ncbi request reprint Embryonic expression of murine 5T4 oncofoetal antigen is associated with morphogenetic events at implantation and in developing epithelia
    Katie M Barrow
    CR UK Immunology Group, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester, United Kingdom
    Dev Dyn 233:1535-45. 2005
    ..Our data demonstrate a limited 5T4 expression profile during embryogenesis associated with actively cycling, undifferentiated epithelial progenitor cells that may contribute to their migration...
  27. ncbi request reprint Association between human leukocyte antigen polymorphism and human papillomavirus 16-positive vulval intraepithelial neoplasia in British women
    Emma J Davidson
    Immunology Group, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester M20 4BX, United Kingdom
    Cancer Res 63:400-3. 2003
    ..Such factors are important to the development of HPV vaccines for treatment of cervical and vulval neoplasia...
  28. pmc Glycosylation and epitope mapping of the 5T4 glycoprotein oncofoetal antigen
    David M Shaw
    CRC Immunology Group, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK
    Biochem J 363:137-45. 2002
    ..The large complex glycosylation at the other sites is likely to influence the antigenicity and tertiary structure generating the 5T4 epitope...
  29. pmc Characterization of the murine 5T4 oncofoetal antigen: a target for immunotherapy in cancer
    Andrew M Woods
    CRUK Immunology Group, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, U K
    Biochem J 366:353-65. 2002
    ..The murine 5T4 antigen-expressing cell lines and antibody reagents are now being used to explore novel immunotherapies in pre-clinical models and the biology of 5T4 in development...
  30. ncbi request reprint Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors
    Kate Mulryan
    Cancer Research United Kingdom Immunology Group, Paterson Institute for Cancer Research, Christie Hospital, Manchester, M20 9BX, United Kingdom
    Mol Cancer Ther 1:1129-37. 2002
    ..Furthermore, mice vaccinated with MVA-m5T4 showed no signs of autoimmune toxicity. These data support the use of MVA-5T4 for tumor immunotherapy...
  31. ncbi request reprint Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival
    Richard W Griffiths
    Department of Medical Oncology, Christie Research Centre, Paterson Institute for Cancer Research, Manchester, UK
    Cancer Immunol Immunother 56:1743-53. 2007
    ..We have investigated the presence of T(Reg) cells systemically and in situ in previously untreated patients with renal cell carcinoma (RCC)...
  32. doi request reprint Poor prognosis associated with human papillomavirus α7 genotypes in cervical carcinoma cannot be explained by intrinsic radiosensitivity
    John S Hall
    Translational Radiobiology Group, Institute of Cancer Sciences, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom
    Int J Radiat Oncol Biol Phys 85:e223-9. 2013
    ..To investigate the relationship between human papillomavirus (HPV) genotype and outcome after radiation therapy and intrinsic radiosensitivity...
  33. ncbi request reprint The use of vaccines in the prevention and treatment of cervical cancer
    Emma J Davidson
    Immunology Group, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester, UK
    Clin Oncol (R Coll Radiol) 14:193-200. 2002
    ..A papillomavirus vaccine that prevented HPV infection on the one hand and acted against established disease on the other, would have a profound impact on one of the major cancers affecting women globally...
  34. ncbi request reprint Significant variations in differentiation properties between independent mouse ES cell lines cultured under defined conditions
    Christopher M Ward
    Immunology Group, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK
    Exp Cell Res 293:229-38. 2004
    ....
  35. ncbi request reprint The 5T4 oncofoetal antigen is an early differentiation marker of mouse ES cells and its absence is a useful means to assess pluripotency
    Christopher M Ward
    Immunology Group, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK
    J Cell Sci 116:4533-42. 2003
    ....
  36. ncbi request reprint No alteration in NK function or zeta chain expression in NK and T cells of cervical cancer patients
    Toli S Onon
    Department of Immunology, Paterson Institute for Cancer Research, Christie Hospital, Manchester, United Kingdom
    Gynecol Oncol 89:120-8. 2003
    ..To investigate in vitro natural killer (NK) cell activity and expression of signal-transducing zeta chains in patients with cervical cancer...
  37. ncbi request reprint Cancer vaccines and immunotherapy
    Said Dermime
    CRC Department of Medical Oncology, University of Manchester and Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester, UK
    Br Med Bull 62:149-62. 2002
    ..Ultimately, this research should give rise to an entirely new modality of cancer treatments...
  38. ncbi request reprint 5T4 interacts with TIP-2/GIPC, a PDZ protein, with implications for metastasis
    Abida Awan
    CRC Immunology Group, CRC Molecular Biology Group, The Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Wilmslow Road, Manchester, M20 4BX, United Kingdom
    Biochem Biophys Res Commun 290:1030-6. 2002
    ..Since other proteins, like 5T4, associate with TIP-2/GIPC and are linked with cancer, we explore the possibility that TIP-2/GIPC may be a common factor involved in the cancer process...
  39. ncbi request reprint The human cytomegalovirus immediate-early promoter is transcriptionally active in undifferentiated mouse embryonic stem cells
    Christopher M Ward
    Immunology Group, Paterson Institute for Cancer Research PICR, Christie Hospital NHS Trust, Manchester, United Kingdom
    Stem Cells 20:472-5. 2002
    ..Therefore, the human CMV promoter remains a useful system for transgene expression in undifferentiated ES cells...
  40. ncbi request reprint Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope
    Anne C Armstrong
    Department of Medical Oncology and Immunology, Cancer Research Campaign, Paterson Institute of Cancer Research, Christie Hospital National Health Service Trust, Manchester, United Kingdom
    J Immunol 168:3983-91. 2002
    ..A single immunization with Ad.A20hFc but not Ad.A20 provided protection in >40% of animals challenged with a lethal dose of the A20 tumor line and was more effective, in this model, than a previously optimized plasmid vaccine...
  41. ncbi request reprint Epithelial-mesenchymal transition events during human embryonic stem cell differentiation
    Angela M Eastham
    Centre for Molecular Medicine, Faculty of Medical and Human Sciences, The University of Manchester, M13 9PT, United Kingdom
    Cancer Res 67:11254-62. 2007
    ..Furthermore, human ES cells represent a useful model system with which to study EMT events relevant to embryonic development and tumor cell metastasis...
  42. pmc E-cadherin inhibits cell surface localization of the pro-migratory 5T4 oncofetal antigen in mouse embryonic stem cells
    Helen L Spencer
    Centre for Molecular Medicine, Faculty of Medical and Human Sciences, The University of Manchester, Manchester M13 9PT, United Kingdom
    Mol Biol Cell 18:2838-51. 2007
    ..We conclude that E-cadherin protein stabilizes cortical actin cytoskeletal arrangement in ES cells, and this can prevent cell surface localization of the promigratory 5T4 antigen...
  43. ncbi request reprint Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species
    Ratish Gambhira
    Department of Pathology, The Johns Hopkins University, Baltimore, Maryland 21231, USA
    Cancer Res 66:11120-4. 2006
    ..001). Vaccination of healthy volunteers thrice with 533-mug HPV16 L2E7E6 at monthly intervals induced L2-specific serum antibodies that neutralized across papillomavirus species. Responses in AGIN patients were infrequent...
  44. ncbi request reprint Targeting immune effector molecules to human tumor cells through genetic delivery of 5T4-specific scFv fusion proteins
    Kevin A Myers
    Oxford BioMedica UK Ltd, Medawar Centre, Oxford Science Park, UK
    Cancer Gene Ther 9:884-96. 2002
    ..Furthermore, the scFv-HIgG1 fusion protein is able to direct lysis of 5T4-expressing human tumor cell lines through antibody-dependent cell cytotoxicity, indicating its potential as a gene therapy for human cancers...
  45. ncbi request reprint Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer
    Andreas M Kaufmann
    Frauenklinik, Friedrich Schiller University of Jena, 07743 Jena, Germany
    Clin Cancer Res 8:3676-85. 2002
    ....
  46. ncbi request reprint TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia
    Renske D M Steenbergen
    Department of Pathology, Unit of Molecular Pathology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    J Natl Cancer Inst 96:294-305. 2004
    ..We assessed the role of the gene encoding the adhesion molecule tumor suppressor in lung cancer 1 (TSLC1) in this progression...
  47. ncbi request reprint Oncofetal antigen 5T4 expression as a prognostic factor in patients with gastric cancer
    Hiroshi Naganuma
    First Department of Surgery, Yamanashi Medical University, Japan
    Anticancer Res 22:1033-8. 2002
    ..Antigen 5T4 is reported to be expressed only on trophoblasts and neoplastic cells and would be a potentially useful marker for neoplastic cells...
  48. ncbi request reprint Bead-isolated human CD4+CD25+ T regulatory cells are anergic and significantly suppress proliferation of CD4+CD25- T responder cells
    Eyad Elkord
    Clin Immunol 120:232-3. 2006